InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Evommune, Inc.

EVMN Clue Score66
United States Fiscal year ends December CIK 0002044725
$6.25 -2.50% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $6.25 −69.11% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 6 Nov 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2024Revenue7.0Operating income−70.0Net income−66.8EPS, diluted−45.29Fiscal year 2025Revenue13.0 +85.7%Operating income−81.1Net income−68.9EPS, diluted−11.22
FY2024FY2025
Revenue 7.0 13.0
Growth +85.7%
Operating income −70.0 −81.1
Net income −66.8 −68.9
Growth
EPS, diluted −45.29 −11.22

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2024Operating margin−1,000.2%Net margin−954.4%Free cash flow margin−832.6%Fiscal year 2025Operating margin−623.6%Net margin−529.8%Free cash flow margin−589.8%
FY2024FY2025
Operating margin −1,000.2% −623.6%
Net margin −954.4% −529.8%
Free cash flow margin −832.6% −589.8%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2024Operating cash flow−58.2Capital expenditure−0.1Free cash flow−58.3Fiscal year 2025Operating cash flow−76.4Capital expenditure−0.2Free cash flow−76.7
FY2024FY2025
Operating cash flow −58.2 −76.4
Capital expenditure −0.1 −0.2
Free cash flow −58.3 −76.7
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2024Cash16.3Shareholders’ equity−144.2Fiscal year 2025Cash44.1Shareholders’ equity205.6
FY2024FY2025
Cash 16.3 44.1
Shareholders’ equity −144.2 205.6

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
−1,000.2% −623.6%
−975.8% −529.8%
−954.4% −529.8%
−832.6% −589.8%
Spending
917.8% 569.6%
182.4% 154.1%
1.3% 1.8%
Returns
n/a −33.5%
−87.8% −30.6%
Balance and payout
37.5% 8.6%